ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VCEL Vericel Corporation

51.1101
1.26 (2.53%)
Last Updated: 14:41:12
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vericel Corporation NASDAQ:VCEL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.26 2.53% 51.1101 51.12 51.44 51.265 49.585 50.66 23,951 14:41:12

Statement of Changes in Beneficial Ownership (4)

31/03/2021 9:18pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hopper Jonathan Mark
2. Issuer Name and Ticker or Trading Symbol

Vericel Corp [ VCEL ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O VERICEL CORPORATION, 64 SIDNEY STREET
3. Date of Earliest Transaction (MM/DD/YYYY)

3/30/2021
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/30/2021  M  5000 A$10.95 27966 D  
Common Stock 3/30/2021  S  5000 D(1)$50.561 22966 D  
Common Stock 3/30/2021  M  8438 A$10.95 31404 D  
Common Stock 3/30/2021  S  1820 D(1)$51 29584 D  
Common Stock 3/30/2021  M  20000 A$10.95 49584 D  
Common Stock 3/30/2021  S  11104 D(1)$51.8412 38480 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $10.95 3/30/2021  M     5000   (2)8/20/2028 Common Stock 5000 $0 86736 D  
Stock Option (right to buy) $10.95 3/30/2021  M     20000   (2)8/20/2028 Common Stock 20000 $0 66736 D  
Stock Option (right to buy) $10.95 3/30/2021  M     8438   (2)8/20/2028 Common Stock 8438 $0 58298 D  

Explanation of Responses:
(1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
(2) These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Hopper Jonathan Mark
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE, MA 02139


Chief Medical Officer

Signatures
/s/ Jonathan Hopper3/31/2021
**Signature of Reporting PersonDate

1 Year Vericel Chart

1 Year Vericel Chart

1 Month Vericel Chart

1 Month Vericel Chart

Your Recent History

Delayed Upgrade Clock